Iovance (NASDAQ: IOVA) CMO awarded 58,750 RSUs as equity compensation

Rhea-AI Filing Summary

GRAF FINCKENSTEIN FRIEDRICH reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Medical Officer, Friedrich Graf Finckenstein, received a grant of 58,750 restricted stock units. Each RSU represents a contingent right to receive one share of common stock.

The RSUs vest over three years, assuming continued employment. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years. After this grant, the reporting person holds 58,750 RSUs directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAF FINCKENSTEIN FRIEDRICH

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/09/2026		A		58,750		(2)	(2)	Common stock	58,750	$0.00	58,750	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

	/s/ Friedrich Graf Finckenstein	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for its Chief Medical Officer?

The Chief Medical Officer, Friedrich Graf Finckenstein, received a grant of 58,750 restricted stock units. These RSUs are compensation, not an open-market share purchase or sale, and each unit represents the right to receive one share of Iovance common stock upon vesting.

How many restricted stock units were granted to the IOVA Chief Medical Officer?

The Chief Medical Officer was granted 58,750 restricted stock units. This entire amount is tied to future vesting conditions and represents potential shares of common stock that may be delivered over time if employment and vesting requirements are satisfied.

What are the vesting terms of the restricted stock units granted by IOVANCE BIOTHERAPEUTICS (IOVA)?

The RSUs vest over three years, subject to continued employment. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the next two years, starting with the first quarter after that anniversary.

Does the IOVA Form 4 filing show any open-market stock purchases or sales by the Chief Medical Officer?

No open-market purchases or sales are reported. The filing shows a compensation-related acquisition of 58,750 restricted stock units at a price of zero, classified as a grant or award rather than a market transaction, with no shares sold in this report.

How many restricted stock units does the IOVA Chief Medical Officer hold after this transaction?

Following this grant, the Chief Medical Officer is reported as holding 58,750 restricted stock units directly. These units will convert into shares of Iovance common stock only as they vest under the three-year vesting schedule described in the filing footnotes.

What does each IOVANCE BIOTHERAPEUTICS (IOVA) restricted stock unit represent in this grant?

Each restricted stock unit represents a contingent right to receive one share of Iovance common stock. Delivery of the underlying shares depends on the RSUs vesting over time and the Chief Medical Officer remaining employed through the specified vesting dates.